Abbvie Inc ABBV

$293.89 +0.59 (0.20%)

Valuation

Market cap
514,924,192,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
P/E (trailing)
22.47
P/E (forward)
20.60
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
3,519,986
Avg volume
4,960,102
Day's range
$291.04 – $294.50
Shares out
1,767,616,000
Stochastic %K
56%
Beta
0.20
Analysts
Moderate Buy
Price target
$305.93

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

Porsche981GT2 Nov 10, 8:52 PM
$ABBV stunning!
0 replies
Gebinator Nov 10, 8:47 PM
$SLS @OnTheBalance the MEGA FLOSS 4: $JNJ $MRK $ABBV $LLY $40 Billy 🦖 MINIMUM
0 replies
TechnoFunctional Nov 10, 5:55 PM
$ABVX has identified α4β7 as its leading candidate mechanism for an Obefazimod combination, they will confirm their molecule for combo before JPM in Jan 27. Following companies have developed molecules that inhibit α4β7 $LLY Zotemtegrast (MORF-057 / LY4268989) $GILD Emvistegrast (GS-1427) — an oral, once-daily α4β7 inhibitor $ABBV ABBV-382 — an anti-α4β7 monoclonal antibody $SNY HXN-1002 — a bispecific antibody targeting both TL1A and α4β7. For a company that already owns an α4β7 molecule, acquiring Abivax could potentially create a combination franchise with two complementary mechanisms. Lilly is particularly interesting here. It already owns an oral α4β7 inhibitor and is actively testing it in combination with mirikizumab. Adding obefazimod could give Lilly another potential combination option, with a different mechanism from both drugs.
1 replies
HydrogenH2 Nov 10, 3:32 PM
$ABBV
0 replies
HydrogenH2 Nov 10, 11:04 AM
$ABBV Payout is @ 281.66% according to Finviz ...
0 replies
55X_ROI_Q1_2026 Nov 9, 10:26 PM
$SLS Phase 3 Results and Share Price Launch -IMMINENT. $MRNA from $25 earlier in the Year to $280 today --- + over $80B in additional Market Value - Based on Phase 3 Registrational Cancer Vaccine Results - SLS is NEXT. P3 results are Imminent for GPs - A revolutionary Immunotherapy to prevent AML Remission and extend survival. While we are seeing Miraculous survival the SLS Phase 3, BAT for Control Patients FAILEDto Increase Survival in 5 recent Clinical trials including 2 AML Remission Trials conducted by $ABBV. And Gps has proven effective in all prior trials, including 2 Separate Phase 2 Trials for AML First and AML Second Remission - with 2x and 4x advantage over BAT. //
1 replies
55X_ROI_Q1_2026 Nov 9, 7:29 PM
$SLS $ABBV Does everyone remember when $ABVX was bumping around from $5 - $10 per share ? and then it T1 Trading Halted when it Announced its P3 Trial Topline Results ? and then Opened UP +600% at $60 Per Share? from $10 to$60 in a heartbeat... and it Kept Climbing to a high of $147 Per Share From $5 to $147 all Based on P3 Trial Results Something very similar is about to Happen HERE> $MRNA just added $80B in Mkt Cap based on its P3 Cancer Vaccine Results.
0 replies
Albino_Trader123 Nov 9, 6:23 PM
$ABBV Still setting up nicely on tight 4 week base. Tried to breakout and flushed it last week. Now trying to reclaim back over the base
0 replies